Applied dna significantly expands addressable market for linea™ covid-19 assay kit via successful amendment to fda eua

Stony brook, n.y.--(business wire)---- $apdn #covid19--applied dna sciences, inc. (nasdaq:apdn) (“applied dna” or the "company"), a leader in polymerase chain reaction (pcr)-based dna manufacturing, announced that the u.s. food and drug administration (fda) has granted an emergency use authorization (eua) amendment that expands the installed base of rt-pcr platforms that can process the company's linea™ covid-19 assay kit. the eua amendment extends the rt-pcr platform authorization from applied biosystems' (therm
APDN Ratings Summary
APDN Quant Ranking